Publications by authors named "Oliver Boix"

Claim this Profile
J
Joint time-to-event partial order continual reassessment method and Joint time-to-event Bayesian logistic regression model: Statistical designs for dual agent phase I/II dose finding studies with late-onset toxicity and activity outcomes.
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki

Stat Methods Med Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials.
Jan Rekowski, Christina Guo, Olga Solovyeva, Munyaradzi Dimairo, Mahtab Rouhifard, Oliver Boix

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, Munyaradzi Dimairo, Olga Solovyeva, Oliver Boix

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity Outcomes.
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki

Stat Biopharm Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Oliver Boix

BMJ· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Oliver Boix

BMJ· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Backfilling cohorts in phase I dose-escalation studies.
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki

Clin Trials· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose finding studies for therapies with late-onset toxicities: A comparison study of designs.
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki

Stat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Jennifer R Diamond, Valentina Boni, Emerson Lim, Grzegorz Nowakowski, Raul Cordoba, Oliver Boix

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiss-Bernhardt, Barbara Deschler-Baier, Oliver Boix

Immunotherapy· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Oliver Boix

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Martin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, Alejandro Navarro, Ross A Soo, Oliver Boix

Lancet Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Robin L Jones, Johanna C Bendell, David C Smith, Konstanze Diefenbach, John Lettieri, Oliver Boix

Cancer Chemother Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Martin Büchert, Oliver Boix

Clin Cancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis